JP2017501711A5 - - Google Patents

Download PDF

Info

Publication number
JP2017501711A5
JP2017501711A5 JP2016541346A JP2016541346A JP2017501711A5 JP 2017501711 A5 JP2017501711 A5 JP 2017501711A5 JP 2016541346 A JP2016541346 A JP 2016541346A JP 2016541346 A JP2016541346 A JP 2016541346A JP 2017501711 A5 JP2017501711 A5 JP 2017501711A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
antibody
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016541346A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017501711A (ja
JPWO2015095539A5 (enExample
JP7325166B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/071193 external-priority patent/WO2015095539A1/en
Publication of JP2017501711A publication Critical patent/JP2017501711A/ja
Publication of JP2017501711A5 publication Critical patent/JP2017501711A5/ja
Priority to JP2020092097A priority Critical patent/JP7504664B2/ja
Publication of JPWO2015095539A5 publication Critical patent/JPWO2015095539A5/ja
Application granted granted Critical
Publication of JP7325166B2 publication Critical patent/JP7325166B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016541346A 2013-12-20 2014-12-18 二重特異性抗体 Active JP7325166B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2020092097A JP7504664B2 (ja) 2013-12-20 2020-05-27 二重特異性抗体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361919552P 2013-12-20 2013-12-20
US61/919,552 2013-12-20
US201461946547P 2014-02-28 2014-02-28
US61/946,547 2014-02-28
PCT/US2014/071193 WO2015095539A1 (en) 2013-12-20 2014-12-18 Dual specific antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020092097A Division JP7504664B2 (ja) 2013-12-20 2020-05-27 二重特異性抗体

Publications (4)

Publication Number Publication Date
JP2017501711A JP2017501711A (ja) 2017-01-19
JP2017501711A5 true JP2017501711A5 (enExample) 2018-02-08
JPWO2015095539A5 JPWO2015095539A5 (enExample) 2022-03-09
JP7325166B2 JP7325166B2 (ja) 2023-08-14

Family

ID=52293284

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016541346A Active JP7325166B2 (ja) 2013-12-20 2014-12-18 二重特異性抗体
JP2020092097A Active JP7504664B2 (ja) 2013-12-20 2020-05-27 二重特異性抗体
JP2023134016A Withdrawn JP2023179409A (ja) 2013-12-20 2023-08-21 二重特異性抗体
JP2025133768A Pending JP2025179073A (ja) 2013-12-20 2025-08-08 二重特異性抗体

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020092097A Active JP7504664B2 (ja) 2013-12-20 2020-05-27 二重特異性抗体
JP2023134016A Withdrawn JP2023179409A (ja) 2013-12-20 2023-08-21 二重特異性抗体
JP2025133768A Pending JP2025179073A (ja) 2013-12-20 2025-08-08 二重特異性抗体

Country Status (10)

Country Link
US (5) US10683348B2 (enExample)
EP (1) EP3083682B1 (enExample)
JP (4) JP7325166B2 (enExample)
KR (3) KR20230155605A (enExample)
CN (2) CN105849124B (enExample)
BR (1) BR112016011027A2 (enExample)
CA (2) CA3204788C (enExample)
MX (2) MX380937B (enExample)
RU (1) RU2732032C2 (enExample)
WO (1) WO2015095539A1 (enExample)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA037960B1 (ru) 2016-04-27 2021-06-15 Эббви Инк. Способ лечения эозинофильного эзофагита с применением антитела против il-13
TW201829463A (zh) 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 抗hla-g抗體及其用途
EP4491234A3 (en) 2017-02-08 2025-04-09 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
BR112019017197A2 (pt) 2017-02-20 2020-04-14 Dragonfly Therapeutics, Inc. proteínas que se ligam a her2, nkg2d e cd16
CN110382696B (zh) * 2017-03-07 2024-04-19 豪夫迈·罗氏有限公司 发现替代性抗原特异性抗体变体的方法
AU2018247767B2 (en) 2017-04-03 2025-01-30 F. Hoffmann-La Roche Ag Antibodies binding to STEAP-1
HUE060019T2 (hu) 2017-04-05 2023-01-28 Hoffmann La Roche Anti-LAG3 antitestek
MX2020003034A (es) 2017-09-29 2020-07-22 Jiangsu Hengrui Medicine Co Anticuerpo il-5, fragmento de union a antigeno del mismo y su aplicacion medica.
EP3728317A2 (en) 2017-12-21 2020-10-28 F. Hoffmann-La Roche AG Antibodies binding to hla-a2/wt1
EP3746470A1 (en) 2018-01-31 2020-12-09 F. Hoffmann-La Roche AG Stabilized immunoglobulin domains
JP2021511793A (ja) 2018-01-31 2021-05-13 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Lag3に結合する抗原結合部位を含む二重特異性抗体
AU2019218125B2 (en) 2018-02-08 2025-03-13 Dragonfly Therapeutics, Inc. Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
PE20220278A1 (es) 2018-02-08 2022-02-25 Dragonfly Therapeutics Inc Dominios variables de anticuerpos que se dirigen al receptor nkg2d
TWI829667B (zh) 2018-02-09 2024-01-21 瑞士商赫孚孟拉羅股份公司 結合gprc5d之抗體
TW201942134A (zh) 2018-02-20 2019-11-01 美商蜻蜓醫療公司 結合cd33、nkg2d及cd16之多特異性結合蛋白及使用方法
JP2021519073A (ja) 2018-03-29 2021-08-10 ジェネンテック, インコーポレイテッド 哺乳動物細胞におけるラクトジェニック活性の制御
AR115052A1 (es) 2018-04-18 2020-11-25 Hoffmann La Roche Anticuerpos multiespecíficos y utilización de los mismos
AR114789A1 (es) 2018-04-18 2020-10-14 Hoffmann La Roche Anticuerpos anti-hla-g y uso de los mismos
EA202190468A1 (ru) 2018-08-08 2021-07-06 Драгонфлай Терапьютикс, Инк. Мультиспецифические связывающие белки, которые связывают bcma, nkg2d и cd16, и способы их применения
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
KR20250112921A (ko) 2018-08-08 2025-07-24 드래곤플라이 쎄라퓨틱스, 인크. Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질
TWI829831B (zh) 2018-12-21 2024-01-21 瑞士商赫孚孟拉羅股份公司 結合cd3之抗體
CN113412123A (zh) 2018-12-28 2021-09-17 豪夫迈·罗氏有限公司 用于免疫应答增强的患者的治疗性用途的肽-mhc-i-抗体融合蛋白
WO2020176478A1 (en) 2019-02-25 2020-09-03 The University Of Chicago Methods and compositions for treating inflammatory and autoimmune conditions with ecm-affinity peptides linked to anti-inflammatory agents
KR20210145187A (ko) 2019-03-29 2021-12-01 지앙수 헨그루이 메디슨 컴퍼니 리미티드 Il-5에 대한 항체를 함유하는 약학적 조성물 및 이의 용도
WO2020201992A1 (en) 2019-04-02 2020-10-08 National Research Council Of Canada Antibody variants with ph-dependent antigen binding for selective targeting of solid tumors
EP3962924A1 (en) 2019-05-03 2022-03-09 Genentech, Inc. Methods of reducing the enzymatic hydrolysis activity rate in a composition obtained from a purification platform
HRP20250475T1 (hr) 2019-06-26 2025-06-06 F. Hoffmann - La Roche Ag Stanične linije sisavaca s deaktivacijom gena sirt-1
AR119393A1 (es) 2019-07-15 2021-12-15 Hoffmann La Roche Anticuerpos que se unen a nkg2d
WO2021018925A1 (en) 2019-07-31 2021-02-04 F. Hoffmann-La Roche Ag Antibodies binding to gprc5d
SG11202112491WA (en) 2019-07-31 2021-12-30 Hoffmann La Roche Antibodies binding to gprc5d
CN114423791B (zh) 2019-09-18 2026-01-09 豪夫迈·罗氏有限公司 抗klk7抗体、抗klk5抗体、多特异性抗klk5/klk7抗体及使用方法
CN114641270A (zh) 2019-11-15 2022-06-17 豪夫迈·罗氏有限公司 防止水性蛋白质溶液中可见颗粒的形成
KR20220100963A (ko) 2019-12-18 2022-07-18 에프. 호프만-라 로슈 아게 Hla-a2/mage-a4에 결합하는 항체
BR112022012010A2 (pt) 2019-12-18 2022-08-30 Hoffmann La Roche Anticorpos, ácido nucleico isolado, célula hospedeira, formulação farmacêutica, uso do anticorpo, método de produção de um anticorpo, método de tratamento de um indivíduo que tem câncer e método de tratamento de um indivíduo que tem uma doença inflamatória ou autoimune
AU2020412609A1 (en) 2019-12-23 2022-06-16 Genentech, Inc. Apolipoprotein L1-specific antibodies and methods of use
BR112022013888A2 (pt) 2020-01-15 2022-09-13 Hoffmann La Roche Métodos para reduzir a quantidade de impurezas não agregadas relacionadas ao produto (napris), produzir uma solução tamponada de anticorpos monoclonais (mabs) e produzir um mab, uso de um filtro de profundidade sintético e solução tamponada de anticorpos monoclonais
JP2023518841A (ja) 2020-03-26 2023-05-08 ジェネンテック, インコーポレイテッド 宿主細胞タンパク質が減少した修飾哺乳動物細胞
EP4146271A4 (en) 2020-05-06 2024-09-04 Dragonfly Therapeutics, Inc. PROTEINS THAT BIND NKG2D, CD16 AND CLEC12A
WO2021228917A1 (en) 2020-05-15 2021-11-18 F. Hoffmann-La Roche Ag Prevention of visible particle formation in parenteral protein solutions
JP2023525898A (ja) 2020-05-19 2023-06-19 エフ. ホフマン-ラ ロシュ アーゲー 非経口タンパク質溶液における可視粒子の形成を防止するためのキレート剤の使用
EP4161644A2 (en) 2020-06-08 2023-04-12 F. Hoffmann-La Roche AG Anti-hbv antibodies and methods of use
AU2021291005A1 (en) 2020-06-19 2023-01-05 F. Hoffmann-La Roche Ag Antibodies binding to CD3 and FolR1
KR20230025665A (ko) 2020-06-19 2023-02-22 에프. 호프만-라 로슈 아게 Cd3에 결합하는 항체
TWI852680B (zh) 2020-06-19 2024-08-11 瑞士商赫孚孟拉羅股份公司 與 cd3 及 cd19 結合之抗體
WO2021255146A1 (en) 2020-06-19 2021-12-23 F. Hoffmann-La Roche Ag Antibodies binding to cd3 and cea
US20220041672A1 (en) 2020-06-24 2022-02-10 Genentech, Inc. Apoptosis resistant cell lines
JP2023532764A (ja) 2020-07-07 2023-07-31 エフ. ホフマン-ラ ロシュ アーゲー 治療用タンパク質製剤の安定剤としての代替界面活性剤
MX2023000617A (es) 2020-07-17 2023-02-13 Genentech Inc Anticuerpos anti-notch2 y metodos de uso.
CN116648507A (zh) 2020-08-28 2023-08-25 基因泰克公司 宿主细胞蛋白的CRISPR/Cas9多重敲除
US20220154207A1 (en) 2020-09-24 2022-05-19 Hoffmann-La Roche Inc. Mammalian cell lines with gene knockout
AR123855A1 (es) 2020-10-20 2023-01-18 Genentech Inc Anticuerpos anti-mertk conjugados con peg y métodos de uso
AU2021376837A1 (en) 2020-11-16 2023-06-15 F. Hoffmann-La Roche Ag Fab high mannose glycoforms
EP4263609A1 (en) 2020-12-17 2023-10-25 F. Hoffmann-La Roche AG Anti-hla-g antibodies and use thereof
WO2022136140A1 (en) 2020-12-22 2022-06-30 F. Hoffmann-La Roche Ag Oligonucleotides targeting xbp1
WO2022157773A2 (en) * 2021-01-21 2022-07-28 Biolojic Design Ltd. Dual binding antibodies, methods of producing dual binding antibodies, and uses thereof
EP4288458A1 (en) 2021-02-03 2023-12-13 Genentech, Inc. Multispecific binding protein degrader platform and methods of use
US12377144B2 (en) 2021-03-03 2025-08-05 Dragonfly Therapeutics, Inc. Methods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and a tumor-associated antigen
JP2024512377A (ja) 2021-03-12 2024-03-19 ジェネンテック, インコーポレイテッド 抗klk7抗体、抗klk5抗体、多重特異性抗klk5/klk7抗体、及び使用方法
EP4320444A1 (en) 2021-04-09 2024-02-14 F. Hoffmann-La Roche AG Process for selecting cell clones expressing a heterologous polypeptide
WO2022225880A1 (en) 2021-04-19 2022-10-27 Genentech, Inc. Modified mammalian cells
KR20240010469A (ko) 2021-05-21 2024-01-23 제넨테크, 인크. 관심 재조합 생성물의 생성을 위한 변형된 세포
JP2024523034A (ja) 2021-06-18 2024-06-25 エフ. ホフマン-ラ ロシュ アーゲー 二重特異性抗ccl2抗体
JP7826449B2 (ja) 2021-07-13 2026-03-09 ジェネンテック, インコーポレイテッド サイトカイン放出症候群を予測する多変量モデル
AU2022315528A1 (en) 2021-07-22 2023-10-19 F. Hoffmann-La Roche Ag Heterodimeric fc domain antibodies
WO2023012147A1 (en) 2021-08-03 2023-02-09 F. Hoffmann-La Roche Ag Bispecific antibodies and methods of use
AR127887A1 (es) 2021-12-10 2024-03-06 Hoffmann La Roche Anticuerpos que se unen a cd3 y plap
JP2025500334A (ja) 2021-12-21 2025-01-09 エフ. ホフマン-ラ ロシュ アーゲー 加水分解活性を決定するための方法
WO2023141445A1 (en) 2022-01-19 2023-07-27 Genentech, Inc. Anti-notch2 antibodies and conjugates and methods of use
AU2023228391A1 (en) * 2022-03-03 2024-09-19 Pfizer Inc. Multispecific antibodies binding to il-4, il-13 and/or tslp and uses thereof
JP2025513335A (ja) 2022-04-19 2025-04-24 エフ. ホフマン-ラ ロシュ アーゲー 改良された産生細胞
KR20240107348A (ko) * 2022-05-23 2024-07-09 리제네코어 바이오테크 컴퍼니 리미티드 안정적인 항체 치료제
AU2023281650A1 (en) 2022-05-30 2024-10-17 Hanall Biopharma Co., Ltd. Anti-fcrn antibody or antigen binding fragment thereof with improved stability
EP4532526A1 (en) 2022-06-03 2025-04-09 F. Hoffmann-La Roche AG Improved production cells
JP2025522482A (ja) 2022-06-17 2025-07-15 アポジー バイオロジクス, インコーポレイテッド インターロイキン13に結合する抗体及び使用方法
CR20250056A (es) 2022-07-22 2025-03-19 Genentech Inc Moléculas de unión al antígeno anti-steap1 y sus usos.
TW202423969A (zh) 2022-10-10 2024-06-16 瑞士商赫孚孟拉羅股份公司 Gprc5d tcb及蛋白酶體抑制劑之組合療法
TW202430211A (zh) 2022-10-10 2024-08-01 瑞士商赫孚孟拉羅股份公司 Gprc5d tcb及imid之組合療法
TW202423970A (zh) 2022-10-10 2024-06-16 瑞士商赫孚孟拉羅股份公司 Gprc5d tcb及cd38抗體之組合療法
WO2024079069A1 (en) 2022-10-12 2024-04-18 F. Hoffmann-La Roche Ag Method for classifying cells
IL320073A (en) 2022-11-23 2025-06-01 Hoffmann La Roche Method for increasing recombinant protein expression
CN119546630A (zh) 2022-12-08 2025-02-28 南京诺唯赞生物科技股份有限公司 特异性结合rsv的抗体
CN120693406A (zh) 2022-12-12 2025-09-23 基因泰克公司 优化多肽唾液酸含量
JP2026505747A (ja) 2023-01-25 2026-02-18 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト Csf1rおよびcd3に結合する抗体
CN120826234A (zh) 2023-03-06 2025-10-21 豪夫迈·罗氏有限公司 抗EGFRvIII/抗CD3抗体与肿瘤靶向性4-1BB激动剂的组合疗法
WO2024191785A1 (en) 2023-03-10 2024-09-19 Genentech, Inc. Fusions with proteases and uses thereof
WO2024206788A1 (en) 2023-03-31 2024-10-03 Genentech, Inc. Anti-alpha v beta 8 integrin antibodies and methods of use
AU2024269754A1 (en) 2023-05-08 2025-10-23 F. Hoffmann-La Roche Ag Targeted interferon alpha fusion proteins and methods of use
WO2024263761A1 (en) 2023-06-22 2024-12-26 Genentech, Inc. Antibodies and uses thereof
WO2025021838A1 (en) 2023-07-26 2025-01-30 F. Hoffmann-La Roche Ag Antibodies binding to cd3
WO2025032069A1 (en) 2023-08-09 2025-02-13 F. Hoffmann-La Roche Ag Mono and multispecific anti-trem2 antibodies, methods and uses thereof
CN121666400A (zh) 2023-08-09 2026-03-13 豪夫迈·罗氏有限公司 单特异性和多特异性抗trem2抗体、其方法和用途
WO2025040567A1 (en) 2023-08-18 2025-02-27 F. Hoffmann-La Roche Ag Protease activatable fc domain binding molecules
JP2025036273A (ja) * 2023-08-30 2025-03-14 ファイザー・インク 多重特異性抗体およびその使用
AR133909A1 (es) 2023-09-25 2025-11-12 Hoffmann La Roche ANTICUERPO QUE SE UNE A C3bBb
WO2025125386A1 (en) 2023-12-14 2025-06-19 F. Hoffmann-La Roche Ag Antibodies that bind to folr1 and methods of use
US20260071002A1 (en) 2023-12-20 2026-03-12 Hoffmann-La Roche Inc. Antibodies binding to ceacam5
WO2025137086A1 (en) 2023-12-20 2025-06-26 Genentech, Inc. Reducing alpha-gal
WO2025133042A2 (en) 2023-12-22 2025-06-26 F. Hoffmann-La Roche Ag Activatable fusion proteins and methods of use
WO2025181189A1 (en) 2024-03-01 2025-09-04 F. Hoffmann-La Roche Ag Antibodies binding to cd3
WO2025215060A1 (en) 2024-04-11 2025-10-16 F. Hoffmann-La Roche Ag Antibodies that specifically bind modified oligonucleotides
WO2026006162A2 (en) 2024-06-24 2026-01-02 Genentech, Inc. B vitamin modulation
WO2026041568A1 (en) 2024-08-20 2026-02-26 F. Hoffmann-La Roche Ag Antibodies binding to cd3 and dotam

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ES2087997T3 (es) 1990-01-12 1996-08-01 Cell Genesys Inc Generacion de anticuerpos xenogenicos.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6165463A (en) 1997-10-16 2000-12-26 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
CN101525384A (zh) * 2000-06-29 2009-09-09 艾博特公司 双特异性抗体及其制备方法和用途
CA2447851C (en) * 2001-06-28 2012-08-28 Domantis Limited Dual-specific ligand and its use
EP1517921B1 (en) * 2002-06-28 2006-06-07 Domantis Limited Dual specific ligands with increased serum half-life
UA94213C2 (ru) * 2004-09-17 2011-04-26 Домантис Лимитед Применение полипептида одноцепочечного антитела, который подавляет активность cd40 или cd40l в приготовлении медикамента для лечения аутоиммунного заболевания
EP2059533B1 (en) * 2006-08-30 2012-11-14 Genentech, Inc. Multispecific antibodies
CL2008000948A1 (es) * 2007-04-02 2008-10-10 Genentech Inc Uso de un antagonista de celulas b para tratar la artritis reumatoide a condicion que se observe la presencia de polimorfismo de nucleotido simple, epitope compartido o ambos en una muestra genetica del paciente.
EP2050764A1 (en) * 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
NZ594665A (en) * 2009-03-20 2013-08-30 Genentech Inc Bispecific anti-her antibodies
JP5901517B2 (ja) * 2009-05-28 2016-04-13 グラクソ グループ リミテッドGlaxo Group Limited 抗原結合性タンパク質
SI2726510T1 (sl) * 2011-05-27 2023-06-30 F. Hoffmann - La Roche Ag Dvojno ciljanje
WO2014165771A2 (en) 2013-04-05 2014-10-09 Genentech, Inc. Anti-il-4 antibodies and bispecific antibodies and uses thereof

Similar Documents

Publication Publication Date Title
JP2017501711A5 (enExample)
RU2016129247A (ru) Антитела с двойной специфичностью
CN104774266B (zh) 白介素-13结合蛋白
JPWO2015095539A5 (enExample)
CA2896548A1 (en) Multivalent binding protein compositions
US20150344566A1 (en) Dual specific binding proteins directed against il-13 and/or il-17
US20140271457A1 (en) Dual Specific Binding Proteins Directed Against TNF
US20130171059A1 (en) Dual variable domain immunoglobulins and uses thereof
JP2019536806A5 (enExample)
JP2017535257A5 (enExample)
JP7257971B6 (ja) 抗cd40抗体、その抗原結合フラグメント、およびその医学的使用
JP2013507929A (ja) Il−1結合蛋白質
JP2018521638A5 (enExample)
JP2017529838A5 (enExample)
TW201031421A (en) IL-1 binding proteins
JP2014503202A (ja) TNF−α結合性タンパク質
EP2928919A2 (en) Blood-brain barrier (bbb) penetrating dual specific binding proteins
JP2017533694A5 (enExample)
JP2010526028A5 (enExample)
TW201527322A (zh) 骨關節炎及疼痛之治療
JP2020514277A5 (enExample)
JP2015503909A5 (enExample)
JP2017507131A5 (enExample)
JP2010520290A5 (enExample)
TW201402608A (zh) Il-1結合蛋白質